Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites (OaSiS)

20 luglio 2022 aggiornato da: Wake Forest University Health Sciences

Implementation Of Smoking Cessation Services Within NCI NCORP Community Sites With Organized Lung Cancer Screening Programs

Evaluate a multi-faceted training program to improve short-term smoking cessation rates (<14 days post-visit) and short (3 months) and sustained abstinence (6 months) among 1,114 enrolled smokers who present for low-dose computed tomography (LDCT) lung cancer screening in 26 community-based practices.

Panoramica dello studio

Stato

Completato

Condizioni

Descrizione dettagliata

We utilize an effectiveness-implementation hybrid design, employing a cluster, randomized control trial of community-based NCORP sites to study the effectiveness of a multi-faceted intervention to improve smoking cessation among lung cancer screening patients, as well as dissemination and implementation (D&I) science to optimize and accelerate translation of findings into clinical practice. We will: (1) Evaluate a multi-faceted training program to improve short-term smoking cessation rates (1-week post-visit) and sustained abstinence (6 months) among 1,114 enrolled smokers (557 in each trial arm) who present for LDCT lung cancer screening in community-based lung cancer screening practices; (2) Characterize the adoption and adaptation of the evidence-based tobacco cessation strategies in 26 community-based LDCT lung cancer screening programs; and (3) Develop and evaluate an implementation toolkit for integrating evidence-based tobacco cessation strategies in community-based LDCT lung cancer screening programs. Qualitative data will be collected from key informants at participating screening programs during and after intervention implementation. Quantitative survey data (baseline, <14 days, 3 months, and 6 months) and saliva specimens (6 months only) will be collected from smoking patients receiving screening within these programs.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

1094

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Delaware
      • Newark, Delaware, Stati Uniti, 19713
        • Helen F Graham Cancer Center
    • Georgia
      • Augusta, Georgia, Stati Uniti, 30912
        • Augusta University Medical Center
      • Savannah, Georgia, Stati Uniti, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96859
        • Tripler Army Medical Center
    • Illinois
      • Mount Vernon, Illinois, Stati Uniti, 62864
        • Good Samaritan Regional Health Center
      • Urbana, Illinois, Stati Uniti, 61801
        • Carle Cancer Center
    • Iowa
      • Ames, Iowa, Stati Uniti, 50010
        • McFarland Clinic PC - Ames
      • Des Moines, Iowa, Stati Uniti, 50314
        • Mercy Medical Center - Des Moines
    • Louisiana
      • Shreveport, Louisiana, Stati Uniti, 71103
        • LSU Health Sciences Center at Shreveport
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48106
        • Saint Joseph Mercy Hospital
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Spectrum Health at Butterworth Campus
      • Royal Oak, Michigan, Stati Uniti, 48073
        • William Beaumont Hospital-Royal Oak
    • Minnesota
      • Waconia, Minnesota, Stati Uniti, 55387
        • Ridgeview Medical Center
    • Missouri
      • Ballwin, Missouri, Stati Uniti, 63011
        • Saint Louis Cancer and Breast Institute-Ballwin
      • Bolivar, Missouri, Stati Uniti, 65613
        • Central Care Cancer Center - Bolivar
      • Branson, Missouri, Stati Uniti, 65616
        • Cox Cancer Center Branson
      • Joplin, Missouri, Stati Uniti, 64804
        • Freeman Health System
      • Joplin, Missouri, Stati Uniti, 64804
        • Mercy Hospital Joplin
      • Rolla, Missouri, Stati Uniti, 65401
        • Delbert Day Cancer Institute at PCRMC
      • Rolla, Missouri, Stati Uniti, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Saint Louis, Missouri, Stati Uniti, 63131
        • Missouri Baptist Medical Center
      • Saint Louis, Missouri, Stati Uniti, 63141
        • Mercy Hospital Saint Louis
      • Saint Louis, Missouri, Stati Uniti, 63109
        • Saint Louis Cancer and Breast Institute-South City
      • Springfield, Missouri, Stati Uniti, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Stati Uniti, 65804
        • Mercy Hospital Springfield
      • Washington, Missouri, Stati Uniti, 63090
        • Mercy Hospital Washington
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89102
        • University Medical Center of Southern Nevada
      • Reno, Nevada, Stati Uniti, 89503
        • Saint Mary's Regional Medical Center
    • New York
      • Bronx, New York, Stati Uniti, 10467
        • Montefiore Medical Center - Moses Campus
    • North Carolina
      • Winston-Salem, North Carolina, Stati Uniti, 27103
        • Novant Health Forsyth Medical Center
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Stati Uniti, 58103
        • Sanford South University Medical Center
    • Ohio
      • Chillicothe, Ohio, Stati Uniti, 45601
        • Adena Regional Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73120
        • Mercy Hospital Oklahoma City
    • Pennsylvania
      • Danville, Pennsylvania, Stati Uniti, 17822
        • Geisinger Medical Center
    • South Carolina
      • Boiling Springs, South Carolina, Stati Uniti, 29316
        • Prisma Health Cancer Institute - Spartanburg
      • Clinton, South Carolina, Stati Uniti, 29325
        • Prisma Health Cancer Institute - Laurens
      • Easley, South Carolina, Stati Uniti, 29640
        • Prisma Health Cancer Institute - Easley
      • Greenville, South Carolina, Stati Uniti, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, Stati Uniti, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greenville, South Carolina, Stati Uniti, 29605
        • Prisma Health Cancer Institute - Butternut
      • Greenville, South Carolina, Stati Uniti, 29605
        • Prisma Health Greenville Memorial Hospital
      • Greer, South Carolina, Stati Uniti, 29650
        • Prisma Health Cancer Institute - Greer
      • Seneca, South Carolina, Stati Uniti, 29672
        • Prisma Health Cancer Institute - Seneca
    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Virginia
      • Richmond, Virginia, Stati Uniti, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Stati Uniti, 23298
        • Virginia Commonwealth University/Massey Cancer Center
    • Wisconsin
      • La Crosse, Wisconsin, Stati Uniti, 54601
        • Gundersen Lutheran Medical Center
      • Milwaukee, Wisconsin, Stati Uniti, 53215
        • Aurora Saint Luke's Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Agrees to have NCORP research personnel serve as the study liaison and another person to serve as the cessation program champion.
  • Agrees to participate in all aspects of the intervention, randomization, and evaluation.
  • Agrees to participate in a confidential 1-on-1 semi-structured interview with the research team.
  • Agrees to have the interview taped, transcribed and qualitatively analyzed.
  • Age ≥18 years
  • Potential participants will be screened using the following question: "Do you smoke cigarettes every day, some days, or not at all?" (BRFSS). A current smoker is anyone responds "every day" or "some days".

Exclusion Criteria:

  • Current use (previous 30 days) of a tobacco dependence treatment including bupropion, varenicline, and nicotine replacement
  • Individuals who use e-cigarettes and who are not smoking cigarettes. Dual users (those who use both e-cigarettes and cigarettes) will still be included in the trial.
  • The presence of a physical or cognitive impairment that would prevent a person from engaging in survey research (such as blindness, deafness, or dementia).
  • Individual has already completed the intended LDCT lung cancer screening for this study.
  • Non-English speaking participants.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intervention

Training of Lung Cancer Screening Personnel on implementation of the United States Public Health Service (US PHS) Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study

Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)

Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study

Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation.

Nessun intervento: Usual Care

No training or performance coaching calls on personnel, just usual clinic practice.

Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Patients With 7-day Sustained Smoking Abstinence Reported in the Patient Survey
Lasso di tempo: 6 months (after baseline)
7-day sustained smoking abstinence will be measured by the question "Have you smoked a cigarette (or other tobacco products), even a puff, in the last 7 days?" in patient survey.
6 months (after baseline)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Salivary Cotinine Test for Non-Smokers
Lasso di tempo: 6 months (after baseline)
7-day Sustained Smoking abstinence will be validated using a salivary cotinine test in non smokers. Abstinence will be determined by percentage of smokers whose tests come back negative for cotinine. Low levels of cotinine less than 15 milligrams per milliliter (mg/mL) would suggest true smoking cessation and levels higher than or equal to 15 mg/mL would suggest they are still smoking.
6 months (after baseline)
Short-term Smoking Abstinence - Patient Survey
Lasso di tempo: 3 months (after baseline)
Short-tem smoking abstinence will be measured as part of the patient survey as the percentage of patients who report that they have not smoked.
3 months (after baseline)
Total Number of Services Participant Reported Received at 14 Days
Lasso di tempo: <= 14 days after baseline
Fidelity to the intervention will be measured by a patient survey that asks patients if they received up to 18 cessation services during the screening visit. This is the total each participant reported receiving and can range from 0 to 18, with higher values representing more services.
<= 14 days after baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Kristie Foley, PhD, Wake Forest University Health Sciences

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 giugno 2018

Completamento primario (Effettivo)

22 febbraio 2021

Completamento dello studio (Effettivo)

22 febbraio 2021

Date di iscrizione allo studio

Primo inviato

19 settembre 2017

Primo inviato che soddisfa i criteri di controllo qualità

19 settembre 2017

Primo Inserito (Effettivo)

25 settembre 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 luglio 2022

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 luglio 2022

Ultimo verificato

1 luglio 2022

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IRB00040071
  • 1R01CA207158-01 (Sovvenzione/contratto NIH degli Stati Uniti)
  • REBAWF-20817CD (Altro identificatore: NCI)
  • NCI-2017-01669 (Identificatore di registro: NCI CTRP)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Descrizione del piano IPD

Wake Forest (WF) NCORP Research Base (RB) is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI National Clinical Trials Network (NCTN)/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials (https://nctn-data-archive.nci.nih.gov/). This will become the primary means for sharing raw data and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide.

Periodo di condivisione IPD

see NIH policy

Criteri di accesso alla condivisione IPD

request using uniform resource locator (URL) below

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Personnel Training and Coaching Calls

3
Sottoscrivi